In breast cancer cells, pharmacological inactivation or genetic knockdown of SCD1 impairs cancer cell growth and inhibits glucose-mediated lipogenesis (Scaglia et al, 2009; Luyimbazi et al, 2010). This evidence concerns the gene SCD and breast cancer.